2013
DOI: 10.1016/j.jprot.2013.04.037
|View full text |Cite
|
Sign up to set email alerts
|

Identification of proteomic signatures associated with lung cancer and COPD

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

2
85
2
1

Year Published

2014
2014
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 123 publications
(90 citation statements)
references
References 61 publications
2
85
2
1
Order By: Relevance
“…Using a proteomic-based approach, we identified HLA class I-bound peptides from epithelial, mesenchymal, and IFNγ-treated mesenchymal cells and demonstrated that identified HLA class I-bound peptides are functional, resulting in lung cancer cell killing. Identified functional peptides include those derived from proteins such as PKM2 that have previously described roles in tumor proliferation and survival, as well as proteins such as SERPBINB1, which is part of a previously described lung cancer proteomic signature (40,41).…”
Section: Discussionmentioning
confidence: 99%
“…Using a proteomic-based approach, we identified HLA class I-bound peptides from epithelial, mesenchymal, and IFNγ-treated mesenchymal cells and demonstrated that identified HLA class I-bound peptides are functional, resulting in lung cancer cell killing. Identified functional peptides include those derived from proteins such as PKM2 that have previously described roles in tumor proliferation and survival, as well as proteins such as SERPBINB1, which is part of a previously described lung cancer proteomic signature (40,41).…”
Section: Discussionmentioning
confidence: 99%
“…Similar to the observations of the present study, CAPS overexpressionhas been found in a range of cancer types, including ovarian cancer (20), ependymoma (14), endometrial cancer (15), lung cancer (16) and colorectal cancer (17). In a study concerning lung cancer and chronic obstructive pulmonary disease (COPD), upregulated CAPS expression was detected in lung cancer and lung cancer with COPD groups when compared with the control group, indicating that CAPS may serve as a biomarker fora lung cancer diagnosis (16). Esophageal cancer is one of the most aggressive cancer types worldwide owing to a lack of early typical symptoms and effective non-invasive diagnostic methods (21).…”
Section: Discussionmentioning
confidence: 99%
“…Smokers develop lung cancer a 10-fold higher than non-smokers. Lung cancer (LC) and chronic obstructive pulmonary disease (COPD) commonly coexist in smokers, and the presence of COPD increases the risk of developing LC [148].…”
Section: Lung Cancermentioning
confidence: 99%